Crispr Therapeutics shares tumble after significant earnings miss
Fortive Corp (NYSE:FTV)’s stock recently reached a 52-week low, touching 46.45 USD. According to InvestingPro data, technical indicators suggest the stock is in oversold territory, potentially presenting an opportunity as the company maintains impressive gross profit margins of nearly 60%. This marks a significant downturn for the company, with InvestingPro data showing a 22.7% decline over the past six months. Despite market pressures, management has been actively buying back shares, demonstrating confidence in the company’s fundamentals. The current price suggests Fortive is undervalued according to InvestingPro’s Fair Value analysis, with 7 additional exclusive insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Fortive Corporation reported its earnings for the second quarter of 2025, with an adjusted earnings per share (EPS) of $0.58, which was slightly below the forecasted $0.59. The company’s revenue for the quarter was $1.02 billion, aligning with expectations. Following these results, Truist Securities downgraded Fortive’s stock from Buy to Hold, citing growth concerns. The downgrade was accompanied by a reduction in the price target from $60.00 to $55.00. This decision came after Fortive’s recent spin-off of PT and the installation of new management, which aims for a more streamlined business portfolio. These developments reflect the ongoing adjustments and challenges Fortive is navigating in its operational strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.